Elizabeth Bunch
Family Medicine · Murfreesboro, TNNPI 1699201327
Payments from drug & device makers
Across 202 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- Novo Nordisk$423
- Otsuka America Pharmaceutical, Inc.$293
- Astellas Pharma US Inc$235
- Lilly USA, LLC$183
- Axsome Therapeutics, Inc.$160
- plus $801 from 21 others
What the payments were for
- Food & beverage$2,993100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $898 |
| Novo Nordisk | 28 | $423 |
| Otsuka America Pharmaceutical, Inc. | 15 | $293 |
| Astellas Pharma US Inc | 16 | $235 |
| Lilly USA, LLC | 15 | $183 |
| Axsome Therapeutics, Inc. | 15 | $160 |
| Esperion Therapeutics, Inc. | 7 | $113 |
| Exact Sciences | 6 | $91 |
| GSK | 6 | $89 |
| Amgen | 5 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $52 |
| Dynavax Technologies Corporation | 5 | $49 |
| Bayer | 2 | $45 |
| Pfizer | 2 | $44 |
| Eisai Inc. | 2 | $29 |
| Merck | 2 | $27 |
| Sanofi | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
| AstraZeneca | 1 | $11 |
How this compares
$2,993 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $117,750 |
| MounjaroTirzepatide | 47 | $57,386 |
| EliquisApixaban | 56 | $47,500 |
| RybelsusSemaglutide | 18 | $28,487 |
| XareltoRivaroxaban | 29 | $28,060 |
| JardianceEmpagliflozin | 18 | $18,800 |
| FarxigaDapagliflozin Propanediol | 15 | $13,718 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $12,087 |
| JanuviaSitagliptin Phosphate | 16 | $11,919 |
| Sumatriptan Succinate | 11 | $6,466 |
| TradjentaLinagliptin | 12 | $6,055 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $5,785 |
| Rosuvastatin Calcium | 275 | $4,460 |
| Atorvastatin Calcium | 303 | $4,229 |
| PremarinEstrogens, Conjugated | 13 | $3,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $423 | $146,23689 claims |
| Lilly USA, LLCMounjaro | $183 | $57,38647 claims |
| PfizerEliquis, Premarin | $44 | $51,13869 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $11 | $30,64042 claims |
| Johnson & JohnsonXarelto | $13 | $28,06029 claims |
| GSKBreo Ellipta, Shingrix | $89 | $15,11425 claims |
| AstraZenecaFarxiga | $11 | $13,71815 claims |
| MerckJanuvia | $27 | $11,91916 claims |
| AbbVieSynthroid | $898 | $2,80644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Murfreesboro
- Scott EllerMurfreesboro$17K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.